REGULATORY
Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions
By Yoshinori Sagehashi October 5, 2023
Japan’s debate on the reimbursement policy of Leqembi (lecanemab), a newly approved Alzheimer’s disease (AD) drug by Eisai, will likely zero in on how to possibly re-price it after listing when it becomes widely available…

LATEST

October 4, 2023
Discussions on the FY2024 drug pricing reform are moving forward. The Central Social Insurance Medical Council’s (Chuikyo) drug pricing subcommittee has already run through overall reform topics and held two hearings with industry organizations. The…
October 4, 2023
CSL Behring and wholesaler partner Alfresa said on October 3 that they have released a service for delivering the hemophilia A therapy Afstyla (lonoctocog alfa) and hemophilia B therapy Idelvion (albutrepenonacog alfa) to the homes of patients.As both medicines developed…
October 4, 2023
The WHO said on October 2 that it recommends Takeda Pharmaceutical’s dengue fever vaccine Qdenga for children between the ages of 6 and 16 who live in areas heavily affected by the mosquito-borne viral disease.The jab has already scored the…

Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…

By Philip Carrigan

“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…

By Yoshinori Sagehashi

A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…

By Ken Yoshino

The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…

By Yoshinori Sagehashi

The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…

By Ken Yoshino

In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA